allopurinol

allopurinol is a medication primarily used to manage conditions associated with high uric acid levels, such as gout and certain types of kidney stones. It is also employed to prevent elevated uric acid, a condition known as hyperuricemia, in patients undergoing chemotherapy for diseases like leukemia or lymphoma. The drug works by inhibiting the enzyme xanthine oxidase, thereby reducing the production of uric acid in the body.

Medical uses

Allopurinol is indicated for the long-term management of gout, helping to prevent painful gout attacks and the formation of tophi. It is also used to prevent tumor lysis syndrome, a metabolic complication that can occur during chemotherapy for cancers such as acute lymphoblastic leukemia. Furthermore, it is prescribed for patients with recurrent calcium oxalate kidney stones associated with high uric acid excretion. The medication is not typically used for treating an acute gout flare, as it may initially exacerbate symptoms; instead, agents like colchicine or nonsteroidal anti-inflammatory drugs are preferred for acute management.

Adverse effects

Common adverse effects include skin rash, nausea, and alterations in liver function tests. A rare but severe hypersensitivity reaction known as allopurinol hypersensitivity syndrome can occur, characterized by severe skin reactions like Stevens-Johnson syndrome, eosinophilia, and systemic organ involvement. Other potential serious effects include bone marrow suppression, leading to conditions such as agranulocytosis, and hepatotoxicity. The risk of severe skin reactions is higher in individuals with certain genetic markers, such as HLA-B*5801, which is more prevalent in populations of Han Chinese or Thai descent.

Pharmacology

Allopurinol is a structural analog of the natural purine base hypoxanthine and acts as a competitive inhibitor of the enzyme xanthine oxidase. This inhibition blocks the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby lowering serum uric acid concentrations. The drug is metabolized in the liver by aldehyde oxidase to its primary active metabolite, oxypurinol, which also inhibits xanthine oxidase and has a much longer half-life. Both allopurinol and oxypurinol are excreted primarily via the kidney, necessitating dosage adjustment in patients with chronic kidney disease.

History

Allopurinol was developed in the 1950s by researchers including Gertrude B. Elion and George H. Hitchings at the Burroughs Wellcome & Company pharmaceutical laboratory. Their work on purine analogs, which earned them the Nobel Prize in Physiology or Medicine in 1988, was initially focused on anticancer agents but led to the discovery of allopurinol's effect on uric acid metabolism. The drug received approval from the U.S. Food and Drug Administration in 1966 and became a mainstay in the management of gout, significantly reducing the reliance on older, less effective therapies like probenecid.

Society and culture

Allopurinol is available as a generic medication and is on the World Health Organization's List of Essential Medicines. It has been the subject of various clinical guidelines, including those from the American College of Rheumatology for the management of gout. The drug's association with severe cutaneous adverse reactions has led to pharmacogenomic testing recommendations in certain populations, as endorsed by organizations like the Clinical Pharmacogenetics Implementation Consortium. In popular culture, references to gout and its treatment occasionally appear, such as in historical depictions of figures like King Henry VIII, though allopurinol itself is a modern therapeutic advancement.

Category:Drugs